Equities researchers at Benchmark started coverage on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a report issued on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Piper Sandler cut shares of Inovio Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $8.00 price target on the stock. in a research report on Friday, March 13th. Stifel Nicolaus boosted their price objective on Inovio Pharmaceuticals from $8.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. BidaskClub upgraded Inovio Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, May 15th. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Inovio Pharmaceuticals in a report on Tuesday, May 12th. Finally, Cantor Fitzgerald upped their target price on Inovio Pharmaceuticals from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Inovio Pharmaceuticals currently has an average rating of “Buy” and an average target price of $11.45.

INO stock traded down $0.16 during trading on Thursday, hitting $14.08. 16,072,802 shares of the company’s stock traded hands, compared to its average volume of 44,361,176. The company has a quick ratio of 8.53, a current ratio of 8.53 and a debt-to-equity ratio of 0.51. Inovio Pharmaceuticals has a 52 week low of $1.91 and a 52 week high of $19.36. The stock has a fifty day moving average price of $10.75 and a two-hundred day moving average price of $5.80.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Inovio Pharmaceuticals had a negative net margin of 4,700.42% and a negative return on equity of 166.85%. The firm had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.55 million. During the same period last year, the firm posted ($0.30) EPS. Research analysts predict that Inovio Pharmaceuticals will post -0.74 EPS for the current year.

In related news, Director David B. Weiner sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $11.14, for a total value of $38,990.00. Following the completion of the sale, the director now owns 828,610 shares of the company’s stock, valued at approximately $9,230,715.40. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director David B. Weiner sold 2,404 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $11.84, for a total value of $28,463.36. Following the completion of the sale, the director now directly owns 827,219 shares of the company’s stock, valued at approximately $9,794,272.96. The disclosure for this sale can be found here. In the last three months, insiders sold 9,404 shares of company stock valued at $100,073. 4.00% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in INO. US Bancorp DE boosted its position in Inovio Pharmaceuticals by 568.3% during the first quarter. US Bancorp DE now owns 6,683 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 5,683 shares during the period. S.A. Mason LLC bought a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $26,000. Ameritas Investment Partners Inc. boosted its position in Inovio Pharmaceuticals by 19.0% during the first quarter. Ameritas Investment Partners Inc. now owns 8,259 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,318 shares during the period. PNC Financial Services Group Inc. boosted its position in Inovio Pharmaceuticals by 79.0% during the first quarter. PNC Financial Services Group Inc. now owns 9,666 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 4,266 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Inovio Pharmaceuticals by 10.2% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 10,250 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 950 shares during the period. 26.22% of the stock is owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Read More: CBOE Russell 2000® Volatility Index

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.